Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBNK-1822H2 in Advanced Esophageal Adenocarcinoma
NCT07622940Phase 2Recruiting
- Sponsor
- Biotech Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
A Phase 2 trial of EBNK-1822H2 in esophageal adenocarcinoma (EAC), sponsored by Biotech Pharmaceutical. Started Mar 2026; status: recruiting.
02
Drugs
EBNK-1822H2
03
Conditions
esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT07622940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07622940.